AVDL

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Charles BrandesBrandes Investment Partners $-24.7M ExitQ2 2024 $25M -- --
Chuck RoyceRoyce & Associates $-820.2K ExitQ2 2024 $820k -- --
Steven CohenPoint72 $-675.6K ExitQ2 2024 $676k -- --
Jim SimonsRenaissance Technologies $-6.9K ExitQ2 2024 $6.9k -- --

Trade AVDL

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

CEO: Gregory J. Divis Jr.
IPO Date: Jun 7, 1996

Market Data

Open: $21.64
High: $21.64
Low: $21.64
Volume: 35M
52W High: $23.57
52W Low: $6.38

Valuation

Market Cap: $2.1B
Enterprise Value: $2.1B

Financials

Free Cash Flow: $-47M
Revenue: $169M
Net Income: $-49M
Cash: $51M
Debt: $1.7M

Events

EarningsMar 2

EPS est. 0.08 · actual -0.05